215 related articles for article (PubMed ID: 36638795)
1. An evolved AAV variant enables efficient genetic engineering of murine T cells.
Nyberg WA; Ark J; To A; Clouden S; Reeder G; Muldoon JJ; Chung JY; Xie WH; Allain V; Steinhart Z; Chang C; Talbot A; Kim S; Rosales A; Havlik LP; Pimentel H; Asokan A; Eyquem J
Cell; 2023 Jan; 186(2):446-460.e19. PubMed ID: 36638795
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
3. A multifunctional AAV-CRISPR-Cas9 and its host response.
Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
[TBL] [Abstract][Full Text] [Related]
4. Adeno-Associated Virus-Mediated Delivery of CRISPR-Cas Systems for Genome Engineering in Mammalian Cells.
Gaj T; Schaffer DV
Cold Spring Harb Protoc; 2016 Nov; 2016(11):. PubMed ID: 27803249
[TBL] [Abstract][Full Text] [Related]
5. Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.
Gu X; Wang D; Xu Z; Wang J; Guo L; Chai R; Li G; Shu Y; Li H
Genome Biol; 2021 Mar; 22(1):86. PubMed ID: 33752742
[TBL] [Abstract][Full Text] [Related]
6. High levels of AAV vector integration into CRISPR-induced DNA breaks.
Hanlon KS; Kleinstiver BP; Garcia SP; Zaborowski MP; Volak A; Spirig SE; Muller A; Sousa AA; Tsai SQ; Bengtsson NE; Lööv C; Ingelsson M; Chamberlain JS; Corey DP; Aryee MJ; Joung JK; Breakefield XO; Maguire CA; György B
Nat Commun; 2019 Sep; 10(1):4439. PubMed ID: 31570731
[TBL] [Abstract][Full Text] [Related]
7. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
[TBL] [Abstract][Full Text] [Related]
8. One-step generation of modular CAR-T cells with AAV-Cpf1.
Dai X; Park JJ; Du Y; Kim HR; Wang G; Errami Y; Chen S
Nat Methods; 2019 Mar; 16(3):247-254. PubMed ID: 30804551
[TBL] [Abstract][Full Text] [Related]
9. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
Bloomer H; Smith RH; Hakami W; Larochelle A
Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
[TBL] [Abstract][Full Text] [Related]
10. Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies.
Roth TL; Li PJ; Blaeschke F; Nies JF; Apathy R; Mowery C; Yu R; Nguyen MLT; Lee Y; Truong A; Hiatt J; Wu D; Nguyen DN; Goodman D; Bluestone JA; Ye CJ; Roybal K; Shifrut E; Marson A
Cell; 2020 Apr; 181(3):728-744.e21. PubMed ID: 32302591
[TBL] [Abstract][Full Text] [Related]
11. Genome engineering using Adeno-Associated Virus (AAV).
Howes R; Schofield C
Methods Mol Biol; 2015; 1239():75-103. PubMed ID: 25408402
[TBL] [Abstract][Full Text] [Related]
12. High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.
Gwiazda KS; Grier AE; Sahni J; Burleigh SM; Martin U; Yang JG; Popp NA; Krutein MC; Khan IF; Jacoby K; Jensen MC; Rawlings DJ; Scharenberg AM
Mol Ther; 2016 Sep; 24(9):1570-80. PubMed ID: 27203437
[TBL] [Abstract][Full Text] [Related]
13. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
14. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
15. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus-mediated gene delivery promotes S-phase entry-independent precise targeted integration in cardiomyocytes.
Kohama Y; Higo S; Masumura Y; Shiba M; Kondo T; Ishizu T; Higo T; Nakamura S; Kameda S; Tabata T; Inoue H; Motooka D; Okuzaki D; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
Sci Rep; 2020 Sep; 10(1):15348. PubMed ID: 32948788
[TBL] [Abstract][Full Text] [Related]
17. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.
Hamilton JR; Tsuchida CA; Nguyen DN; Shy BR; McGarrigle ER; Sandoval Espinoza CR; Carr D; Blaeschke F; Marson A; Doudna JA
Cell Rep; 2021 Jun; 35(9):109207. PubMed ID: 34077734
[TBL] [Abstract][Full Text] [Related]
19. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
20. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
